

2009 CMHC Complimentary CME Now Available Online



Did you miss the 2009 Cardiometabolic Health Congress?
No worries, now is your chance to view select presentations & earn CME credit.

Earn up to 24 hours of ACCME, ANCC, or CDR-ADA credit.
All activities are complimentary and registration is not required.

Get Started Today!

- **Advances in Peptide Hormone Therapy: Implications for Obesity, Diabetes, and Cardiometabolic Risk Management**
Louis Aronne, MD; Harold Lebovitz, MD; Carol Wysham, MD
Supported by an educational grant from Amylin
- **Hypertension and CV Risk Reduction: The Role of New Generation Beta Blockade**
Thomas Giles, MD; R. Preston Mason, PhD; Raymond Townsend, MD
Supported by an educational grant from Forest Laboratories
- **High-Dose Insulin Therapy for Patients with T2DM and Severe Insulin Resistance: Comprehensive Clinical Update and Expert Recommendations**
Wendy Lane, MD; Jay Skyler, MD
Supported by an educational grant from Eli Lilly and Company
- **Advances in the Clinical Management of Obesity: Implications of Therapies in Late-Stage Development**
Caroline Apovian, MD; Louis Aronne, MD; Kenneth Fujioka, MD
Supported by an educational grant from Orexigen Therapeutics, Inc.
- **Advances in Dual Anti-Platelet Therapy: Optimizing Anti-Thrombotic Therapy in Patients with ACS**
Jeffrey Anderson, MD; Christopher Cannon, MD; Marc Sabatine, MD
Supported by an educational grant from Daiichi Sankyo, Inc. and Eli Lilly and Company
- **Glucose Control and Beyond: The Multiple Roles of Incretin Therapy in the Management of Type 2 Diabetes and Cardiometabolic Risk**
Harold Lebovitz, MD; Richard Pratley, MD; Bernard Zinman, MD
Supported by an educational grant from Novo Nordisk
- **Targeting the Endothelin Pathway: Novel Strategies to Delay Disease Progression and Improve Outcomes in Pulmonary Arterial Hypertension**
Michael Landzberg, MD; Ioana Preston, MD; Jeffrey Sager, MD
Supported by an educational grant from Actelion Pharmaceuticals, Inc
- **The Emerging Role of Biomarker Panel Assays in Diabetes Prevention: Identifying High-Risk Patients Before It's Too Late**
Richard Bergman, PhD; Ralph DeFronzo, MD; Darren McGuire, MD; Jay Skyler, MD
Supported by an educational grant from Tethys Bioscience
- **Clinical Dilemmas in Managing the Hypertensive Patient with Osteoarthritis**
Michael Farkouh, MD; Alan Gradman, MD; R. Preston Mason, PhD; William White, MD
Supported by an educational grant from NicOx, Inc.
- **New Treatment Paradigms for Comprehensive Cardiometabolic Risk Reduction: The Role of GLP-1 Receptor Agonists in the Management of T2DM, Obesity, Hypertension & Dyslipidemia**
Ralph DeFronzo, MD; David Kendall, MD; Anne Peters, MD
- **Global Cardiometabolic Risk Reduction: Targeting the Multiple Mechanisms Underlying Type 2 Diabetes, Dyslipidemia, and Hypertension**
Om Ganda, MD; Ronald Goldberg, MD; Joseph Izzo Jr, MD; Suzanne Oparil, MD

- **Oral Anti-Hyperglycemic Therapy and Cardiovascular Risk Reduction: Yes It Is Possible!**
Anthony Cincotta, PhD; Robert Cooper, MD; J. Michael Gaziano, MD; Jay Skyler, MD
Supported by an educational grant from VeroScience



www.cardiometabolichealth.org
This activity is jointly sponsored by HealthScience Media, Inc. & Medical Education Resources, Inc.

